Will Arrowhead Stock Rebound After A Large 30% Decline Last Week?
- Wednesday, July 7, 2021, 10:09
- Market
- Add a comment
The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. The decline came after the company decided to pause its early stage clinical trials for AROENaC1001, the company’s investigational treatment.
About the Author
admin123 has written 23527 stories on this site.
